Predicted 25-hydroxyvitamin D over the Adult Lifetime and the Risk of Ovarian Cancer

Overview

Journal Am J Epidemiol

Publisher Oxford University Press

Specialty Public Health

Date 2024 May 16

PMID 38754871

Authors

Jennifer A Ritonja

Coraline Danieli

Magnoudewa Priscille Pana

Michael J Palmer

Kevin LEsperance

Vikki Ho

Michal Abrahamowicz

Anita Koushik

Affiliations

Soon will be listed here.

Abstract

The evidence from previous studies of serum 25-hydroxyvitamin D (25(OH)D) and ovarian cancer risk is not conclusive. However, the 25(OH)D levels were generally only measured in late adulthood, which may not capture the etiologically relevant exposure periods. We investigated predicted 25(OH)D over the adult lifetime in relation to ovarian cancer risk in a population-based case-control study conducted from 2011 to 2016 in Montreal, Canada (n = 490 cases and 896 controls). Predicted 25(OH)D was computed using previously validated regression models. Unconditional multivariable logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% CIs for average predicted 25(OH)D over the adult lifetime and ovarian cancer risk. In addition, the relative importance of different periods of past 25(OH)D exposure was explored using a weighted cumulative exposure (WCE) model. For each 20-nmol/L increase in average predicted 25(OH)D over the adult lifetime, the aOR (95% CI) was 0.73 (0.55-0.96). In WCE analyses, the inverse association was strongest for exposures 5 to 20 years and 35 to 55 years prior to diagnosis, with aORs (95% CIs) of 0.82 (0.69-0.94) and 0.79 (0.66-1.02), respectively, for each 20-nmol/L increase in predicted 25(OH)D. These results support an inverse association between 25(OH)D levels in adulthood and ovarian cancer risk. This article is part of a Special Collection on Gynecological Cancers.

References

Zheng W, Danforth K, Tworoger S, Goodman M, Arslan A, Patel A . Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172(1):70-80. PMC: 2892541. DOI: 10.1093/aje/kwq118. View

Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Kostenberger M, Tmava Berisha A . Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020; 74(11):1498-1513. PMC: 7091696. DOI: 10.1038/s41430-020-0558-y. View

Wu E, Guo J, Wang K, Xu H, Xie T, Tao L . Association of serum 25-hydroxyvitamin D with the incidence of 16 cancers, cancer mortality, and all-cause mortality among individuals with metabolic syndrome: a prospective cohort study. Eur J Nutr. 2023; 62(6):2581-2592. DOI: 10.1007/s00394-023-03169-x. View

Sajo E, Okunade K, Olorunfemi G, Rabiu K, Anorlu R . Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria. Ecancermedicalscience. 2020; 14:1078. PMC: 7434510. DOI: 10.3332/ecancer.2020.1078. View

Tworoger S, Lee I, Buring J, Rosner B, Hollis B, Hankinson S . Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(4):783-8. DOI: 10.1158/1055-9965.EPI-06-0981. View

Cranney A, Horsley T, ODonnell S, Weiler H, Puil L, Ooi D . Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep). 2007; (158):1-235. PMC: 4781354. View

Royston P, Ambler G, Sauerbrei W . The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999; 28(5):964-74. DOI: 10.1093/ije/28.5.964. View

Ahonen M, Zhuang Y, Aine R, Ylikomi T, Tuohimaa P . Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000; 86(1):40-6. DOI: 10.1002/(sici)1097-0215(20000401)86:1<40::aid-ijc6>3.0.co;2-e. View

Ong J, Dixon-Suen S, Han X, An J, Liyanage U, Dusingize J . A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nat Commun. 2021; 12(1):246. PMC: 7801600. DOI: 10.1038/s41467-020-20368-w. View

10.

Manson J, Cook N, Lee I, Christen W, Bassuk S, Mora S . Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2018; 380(1):33-44. PMC: 6425757. DOI: 10.1056/NEJMoa1809944. View

11.

Ong J, Cuellar-Partida G, Lu Y, Fasching P, Hein A, Burghaus S . Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016; 45(5):1619-1630. PMC: 5100621. DOI: 10.1093/ije/dyw207. View

12.

Budhathoki S, Hidaka A, Yamaji T, Sawada N, Tanaka-Mizuno S, Kuchiba A . Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan Public Health Center-based Prospective Study cohort. BMJ. 2018; 360:k671. PMC: 5838719. DOI: 10.1136/bmj.k671. View

13.

Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb W . Hormonal and reproductive factors and the risk of ovarian cancer. Cancer Causes Control. 2017; 28(5):393-403. DOI: 10.1007/s10552-016-0848-9. View

14.

Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia S . Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res. 2005; 11(1):323-8. View

15.

Bertrand K, Giovannucci E, Liu Y, Malspeis S, Eliassen A, Wu K . Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr. 2012; 108(10):1889-96. PMC: 3346859. DOI: 10.1017/S0007114511007409. View

16.

Sahota H, Barnett H, Lesosky M, Raboud J, Vieth R, Knight J . Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):232-8. DOI: 10.1158/1055-9965.EPI-07-0632. View

17.

Bakhru A, Mallinger J, Buckanovich R, Griggs J . Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: a study from the NHANES. Gynecol Oncol. 2010; 119(2):314-8. DOI: 10.1016/j.ygyno.2010.07.006. View

18.

Prat J . Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017; 41:15-30. DOI: 10.1016/j.bpobgyn.2016.08.007. View

19.

Toriola A, Surcel H, Calypse A, Grankvist K, Luostarinen T, Lukanova A . Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer. 2010; 46(15):2799-805. DOI: 10.1016/j.ejca.2010.05.019. View

20.

Arslan A, Clendenen T, Koenig K, Hultdin J, Enquist K, Agren A . Circulating vitamin d and risk of epithelial ovarian cancer. J Oncol. 2009; 2009:672492. PMC: 2735000. DOI: 10.1155/2009/672492. View